JPRN-jRCT1080223223已完成3 期
An Opened, Non-controlled, Multi-center Study of M118102 in Subjects with Asteatosis
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
The efficacy of M118102 was confirmed as the effects of the soft ointment were maintained after switched to M118102. There were no safety issues associated with M118102.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Asteatosis Patients
排除标准
- •(1) Patients with a history of any of the following:
- •1) Serious allergy (shock, anaphylactic symptoms)
- •2) Allergy to heparinoid
- •3) Cutaneous hypersensitivity to topical medicines (such as contact dermatitis)
- •4) Hemorrhagic blood disorder (hemophilia , thrombocytopenia , purpura )
- •(2) Patients with the following concurrent diseases:
- •1) Patients with any disorders that should not be enrolled in the sutdy such as;
- •-severe cardiac disorders
- •-severe hepatic disorders
- •-severe pulmonary disorders
- •-severe gastrointestinal disorders
- •-severe blood disorders
- •2) Supervening skin disease on Asteatosis
- •3) Hemorrhagic blood disorder (hemophilia , thrombocytopenia , purpura )
- •(3) Pregnant women, women who may be pregnant, lactating women or women who wish to become pregnant or women who are unwilling to use a suitable method of contraception as directed by the principal investigator or sub-investigator.
研究者
相似试验
已完成
2 期
AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type PsoriasisPsoriasisNCT01300052Pfizer68
已完成
2 期
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic DermatitisDermatitis, AtopicNCT01602341Pfizer86
已完成
3 期
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal WomenOsteopeniaNCT00310531Bayer500
已完成
4 期
Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.Alpha 1-proteinase Inhibitor DeficiencyEmphysemaNCT00670007CSL Behring140
已完成
3 期
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMDNeovascular Age-related Macular DegenerationNCT03386474Novartis Pharmaceuticals151